Reinforcing cancer immunotherapy with engineered porous hollow mycobacterium tuberculosis loaded with tumor neoantigens
The results of our study highlight the potential clinical translation of personalized tumor neoantigen vaccines using the phMTb carrier.
Authors
- Wu-Ping Zheng (ORCID: https://orcid.org/0000-0003-0259-0457)
- Feng‐Ying Huang (ORCID: https://orcid.org/0000-0001-9677-6855)
- Guang‐Hong Tan (ORCID: https://orcid.org/0000-0002-6406-0331)
- Hengyu Chen (ORCID: https://orcid.org/0000-0001-9637-3992)
- Jie Jiang (ORCID: https://orcid.org/0009-0007-3377-3033)
- Shu-Zhen Dai
- Minghui Chen (ORCID: https://orcid.org/0009-0001-2086-2914)
- Ri-Hong Wu (ORCID: https://orcid.org/0009-0005-4094-4086)
- Wan Xie
Institutions
- Hainan Medical University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1136/jitc-2024-010150
- Citations
- 5
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 3.99
Funders
- National Natural Science Foundation of China